01 Nov, 2022 RNAi Roundtable: CNS Delivery and ALN-APP, an Investigational RNAi Therapeutic in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Posted at 10:50h
in Capella
On November 1, 2022, we hosted an online RNAi roundtable to review Alnylam’s CNS delivery platform and ALN-APP, an investigational RNAi therapeutic in development for Alzheimer’s Disease and cerebral amyloid angiopathy.
Access the replay
View the presentation
Eric Green
Senior Vice President, Development Programs
Kirk Brown, Ph.D.
Senior Director, Research, CNS Program
Tim Mooney
Director, Program Leader, ALN-APP Program
